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Can doubling the maintenance dose of clopidogrel prevent from early stent 







  BACKGROUND: Treatment of significant coronary artery disease with primary percutaneous 
coronary intervention (PCI) seems better than angioplasty balloon; because the incidence of 
restenosis is lower in this method, however, a serious complication of PCI is stent thrombosis 
which would lead to repeated myocardial infarction (MI) and increase the mortality and 
morbidity. One of the frequent medications which is used to prevent from stent thrombosis is 
clopidogrel, but, stent thrombosis was seen in many of the patients despite given the 
c o n v e n t i o n a l  d o s a g e  o f  t h i s  d r u g .  T h i s  s t u d y  aimed to evaluate the effect of doubling the 
maintenance dose of clopidogrel to prevent from early stent thrombosis, MI and mortality rate. 
 METHODS:  This was a clinical trial study which was done in Shahid Chamran Hospital in 
winter 2010 in Isfahan, Iran. A total of 400 patients with PCI were prospectively followed-up for 
30 days. All the patients were randomly allocated into two groups. The control group received a 
maintenance dose of 75 mg clopidogrel while the case group received 150 mg clopidogrel after 
the initial dosage of 600 mg for 30 days after the PCI.  The incidence of primary outcome such 
as total mortality was recorded during the study. 
 RESULTS: Early stent thrombosis was observed in 4 patients (1%) (One subject in the control 
group and 3 in the case group) during the first 30 days after PCI, but the difference was not 
significant between the two groups (P = 0.62). Mortality due to stent thrombosis occurred in 2 
patients in the case group which showed no significant difference in this group (P = 0.5). In 
addition, MI occurred in 2 patients (1 in each group) which also showed no significant difference 
between the two groups (P = 1). Drug complication such as major bleeding had no significant 
difference between the two groups (P = 0.9). 
  CONCLUSION: The present study showed that doubling dose of clopidogrel could not reduce 
the incidence of early stent thrombosis, mortality and myocardial infarction in comparison with 
conventional dosage; therefore it is recommended that more studies be done in Iranian and 
Asian race for clinical decision-making to prevent form stent thrombosis using high dose of 
clopidogrel. 
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Introduction 
Increasing incidence of cardiovascular disease 
particularly coronary artery diseases has enlarged the 
mortality rate due to prevalence of this group of 
disease all over the world, and it has reached the 
world’s top 10 mortality causes.1 On the other hand, 
high incidence of these diseases caused increasing 
progression and advancement of new techniques and 
methods to treat such diseases.2 Naturally, invented 
techniques and tools to treat cardiovascular disease 
induce some complications for the patients. The tools 
which are highly applicable and effective for the 
patients with coronary artery stenosis and 
atherosclerosis are stents which are inserted for the 
patients in most of the medical and specialized 
cardiovascular centers. Despite its efficacy and high 
efficiency for saving the patients’ life, stents have also 
a series of complication that sometimes lead to 
death.3 According to the conducted studies, the 
prevalence of these complications in the patients 
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undergoing stenting is 5-10 percent. The most 
important short-term complications in the studied 
patients are as the following: 
1. Mortality: Death with all the cases 
2. Myocardial Infarction: Increasing total CK ≥ 2 
times the upper limit of normal or CK MB ≥ 20 
(ng/ml) with or without the presence of new 
pathologic Q waves in at least two continuous leads. 
3. Urgent Target Vessel Revascularization: 
Repeated PCI or surgery at the same treated vein. 
4. Stroke 
5. Acute thrombosis due to stent: As angiographic 
evidence of thrombus at the lesion site. 
6. Angiographic complications: Including coronary 
dissection and coronary perforation. 
One of the most serious stenting complications is 
the stent thrombosis which is considered as acute 
stent thrombosis (less than 24 hours), subacute stent 
thrombosis (24 to 30 days) and delayed stent 
thrombosis (30 days to 1 year).4 Early stent 
thrombosis includes acute and subacute cases which 
are identified based on clinical, angiography and 
pathological criteria and usually are associated with 
serious and lethal complications, increase in mortality 
and morbidity and recurrent infarction. Furthermore, 
it can prolong the duration of hospitalization of the 
patients in the hospital and cause imposing exorbitant 
costs on them. 
At the initial experiences of primary percutaneous 
coronary intervention, the incidence of early stent 
thrombosis was associated with more than 24% of the 
cases; however, following the use of antiplatelet 
aspirin and ticlopidine drugs and acquiring 
appropriate techniques of stenting, this figure 
declined to less than 2 percent.1 
Clinical definition of the stent thrombosis includes 
each of the following items 30 days after the primary 
percutaneous coronary intervention.1 
1. Observing stent occlusion based on 
angiographic criteria. 
2. Sudden death without any clear reason when 
not sure about patency of the stent. 
3. Myocardial infarction or need to emergency 
revascularization  
In a study, the prevalence of mortality following 
the early stent thrombosis is reported 7-25 percent 
which the major prognostic factors included 
inadequate patency of the stents, residual tear and 
inadequate inhibition of the platelet aggregation.5 
In order to prevent from dangerous and deadly 
complications, various factors have been studied; the 
most important of which are using platelet inhibitory 
drugs. Conventional and routine dose of these drugs 
are about 75-325 mg Aspirin and 300-600 mg 
Clopidogrel which the dosage would be different 
based on the type of the applied stents, the time of 
using and the dose of these two drugs. Using 150 mg 
Clopidogrel is recommended for the patients who 
have left main coronary artery involvement or if the 
only patent vessel of the patients had been PCI.1 
It is recommended that combination of 
maintenance treatment be used for one year after the 
primary percutaneous coronary intervention and the 
combination of these two rugs also be used for at 
least 6 weeks.6 One of the other causes of stent 
thrombosis is resistance to aspirin and Clopidogrel 
and/or inadequate dose these drugs in inhibiting the 
platelets. In a study, the comparison of Aspirin and 
Clopidogrel in inhibiting the platelets and resistance 
to them showed that stent thrombosis was more due 
to aspirin-resistance and increasing the dose of this 
drug had no effect on platelet inhibition.4 
In a clinical trial study which was done by Steven 
in North America in 2011, 2116 patients who 
underwent PCI surgery were studied. In this study, 
1053 patients (case group) received 300 mg 
Clopidogrel and the control group (1053 patients) 
received a daily placebo pill 3 to 24 hours before the 
surgery. Moreover, all the patients received 75 mg 
Clopidogrel for 28 days after the surgery and from the 
29th day to the next 12 months after the surgery, the 
first group received 75 mg Clopidogrel while the 
control group received placebo. The results of the 
study after one year follow-up indicated that 
Clopidogrel could reduce the relative risk of mortality, 
myocardial infarction and stroke rate to 26.9%. In 
addition, taking Clopidogrel at least 6 hours before 
the surgery could reduce the relative risk of mortality 
rate to 38.6%. The mortality rate had no significant 
difference between the Clopidogrel group and 
placebo group since the 29th day to one year after the 
surgery7 which was in accordance with the results of 
the present study. 
In another study, 2954 patients underwent primary 
percutaneous coronary intervention; it was concluded 
that doubling the dose of Clopidogrel could reduce 
mortality, MI and stent thrombosis in the first 15 days 
after the PCI.8 
Considering the different results of various 
studies, the fact is that there are still not adequate 
available documents for a decisive conclusion. 
Therefore, the present study aimed to evaluate the 
effect of doubling the maintenance dose of 
Clopidogrel on early stent thrombosist. 
Materials and Methods 
This clinical trial study was done in winter 2010 in 
Shahid Chamran Hospital in Isfahan. The study 
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population included all the patients with coronary 
stenosis who underwent stenting. Sampling method 
was done in simple consecutive sampling. The 
inclusion criteria included patients with marked 
coronary artery stenosis, candidates for stenting and 
desire to participate in the study. The exclusion criteria 
included stenosis in left main coronary artery and 
proximal part of LAD, allergy to Clopidogrel, 
implementing angioplasty, history of MI in the past 
month, symptoms toward congestive heart failure and 
stenting on the only patent vessel of the patient. 
After selecting and obtaining the consent form, the 
patients were given the initial dose of 600 mg 
Clopidogrel one day before the PCI. The patients used 
two type of stents; Bare Metal Stent (BMS) and Drug 
Eluted Stent. The patients, who had PCI complications 
such as incomplete wall, dissection apposition or stent 
under expansion, were excluded from the study. 
Thereafter, the rest of the patients were divided into 
two groups with random allocation method. The first 
group was given 75 mg Clopidogrel once a day for 30 
days. The second group also was given 75 mg 
Clopidogrel twice a day for 30 days. The mentioned 
patients were followed-up at the end of second and 
fourth weeks and the results were recorded in their 
files. Besides, the patients were recommended to 
contact the researcher if any problem such as bleeding 
or fever happened. The data was collected using a 
checklist which had been designed to do so through 
interviewing with the patients and their relatives, 
observing the patients’ status and also results of the 
angiography and physical examination. Collection of 
the data was conducted by referring the researcher to 
the patients’ beds and examination and also 
interviewing them to complete the checklist. 
In order to review the drug complications such as 
bleeding, neutropenia (less than 1500 counts), 
thrombotic thrombocytopenia purpura (TTP) and also 
gastrointestinal symptoms, hive and purities one month 
later, the patients were contacted and additional test 
(complete blood count, …) was performed. 
The data of the study, after collecting and revising 
were analyzed using Software SPSS17. The statistical 
tests for analyzing the data used in this study included 
chi-square and if necessary, Fisher’s exact test (to 
compare between the qualitative data) and logistic 
regression and student’s T tests. 
Results 
In this study, 517 patients underwent stenting surgery 
out of which 117 cases were excluded from the study 
due to not using Plavix® and finally 400 patients 
entered the study. Among 400 patients, 195 of them 
took Plavix daily (control group), and 205 of them (as 
the case group) received doubled dose of Clopidogrel. 
Mean age of the total studied patients was 60.2 ± 11.5 
years. Minimum and maximum age of them was 31 and 
87 years, respectively. 128 patients in the control group 
and 136 patients in the case group were males (65.3% 
vs. 66.3%) and mean age of the males and females of 
the study was 59.3 ± 11.7 and 61.7 ± 10.9 years, 
respectively. 
In this study, 184 of the patients (46%) had blood 
pressure (systolic BP equal/more than 140 or diastolic 
BP equal/more than 90), 62 of them (15.5%) had high 
blood fats (LDL ≥ 100; TG ≥ 250) 77 of them (19.3%) 
had diabetes HDS ≥ 45; FBS ≥ 126), 77 patients were 
smoker and 11 patients had mild to moderate renal 
failure (GFR < 60). The prevalence of these risk 
factors in the two groups is shown in Table 1. 
In 95 patient in the control group and 92 patients 
in the case group, one stent had been inserted (48.7% 
vs. 44.9%). Furthermore, in 100 patients in the case 
group and 113 patients in the control group, two 
stents had been used (51.3% vs. 55.1%). Chi-square 
test also showed no significant difference between the 
two groups in terms of the number of the applied 
stents (P = 0.51). 
 
Table 1. Frequency distribution of the cardiovascular risk factors in both groups 
Risk factors  Control group  Case group  P 
Number Percentage Number Percentage 
HTN 87  44.6  97  47.3  0.59 
HLP 27  13.8  35  17.1  0.37 
DM 40  20.5  37  18  0.53 
Smoking 41  21  36  17.6 0.38 
Renal Failure  6  0.03  5  0.02  0.9 
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Chart 1. Frequency percentage of the artery stentingin the patients 
 
 
Out of 321 applied stent in the control group, 254 
of them were BMS (79%) and in the case group, out of 
292 stents, 214 of them were BMS (73%) which the 
difference was not statistically significant (P = 0.7). 
The frequency of artery stenting results is shown in 
chart 1. Moreover, in 8 patients (2%), more than one 
artery had been stenting such as using LAD and RCA 
which had been applied in 3 patients. 
The average length of used stents in the study 
subjects was 21.7 ± 8.1 mm and according to 
student’s T test, the difference in length of the stents 
in the two groups was not significant (P = 0.09). 
According to the obtained results during the study, 
4 cases of stent thrombosis occurred in the studied 
patients and cumulative incidence of stent thrombosis 
one month after the PCI surgery was 1%. 
One case of thrombosis occurred in the control 
group (0.5%) and 3 cases in the case group (1.5%), 
however, Fisher’s exact test showed that frequency 
distribution of stent thrombosis in the two groups 
had no significant difference (P = 0.62). 
According to the results during the study, two 
deaths happened in all the patients. Hence, the 
incidence of mortality during one month after the 
primary percutaneous coronary intervention was 
equal to 0.5%. It should be noted that the both cases 
of mortality were related to the group consuming 
doubled dose of Plavix, but Fisher’s exact test showed 
no significant correlation between mortality and dose 
of Plavix (P = 0.5). The both subjects passed away at 
the age of 55. 
One month after the PCI surgery, two subjects 
suffered from recurrent myocardial infarction. Hence, 
the incident rate of recurrent MIin these patients was 
0.5%. One of the subject with recurrent MIwas in the 
case group and the other was in the control group and 
according to Fisher’s exact test, recurrent MIhad also 
no difference between the two groups (P = 1). 
Life-threatening complications including excessive 
bleeding, neutropenia and thrombotic 
thrombocytopenia purpura (TTP) or gastrointestinal 
and cutaneous complications were not observed in 
none of the groups. However, nose bleeding was 
recorded in 3 cases in the case group and 2 cases in 
the control group which was not significant between 
the two groups (P = 0.9). 
Discussion 
The main objective of the present study was to 
evaluate the effect of doubling the maintenance dose 
of Clopidogrel to prevent from early stent thrombosis 
after stenting in the patients with coronary artery 
stenosis. 
Mean age of the patients was 60.2 ± 11.5 years. 
The studied results showed that approximately 83 
percent of those who die due to cardiovascular 
diseases are at the age of 65 and more. Hence, age is 
considered as one of the major risk factors for 
incidence of MI and with increase of age, the risk of 
cardiovascular diseases would be more.9 In terms of 
gender distribution, 65.6% and 66.3% of the subjects 
of the control and case groups were males 
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respectively. Different studies around the world have 
shown that males suffer heart attack in lower ages 
compared to females.10 
In this study, stent thrombosis was studied as the 
main dependent variable and at the end of the study; 
there was no significant difference between the case 
group that consumed doubled dose of Clopidogrel 
and the control group that consumed the 
conventional dose of this drug. In other words, 
increased dose of this drug had no effect on 
prevention from thrombosis in patients who 
underwent stenting.  
In a prospective study which was done by Andrew 
in 2005, the patients were followed-up in terms of 
incidence of stent thrombosis one month after the 
PCI (for the early stent thrombosis) for the averagely 
1.5 year after it.11 The incidence rate of stent 
thrombosis was reported 0.5% which compared to 
the present study (1%) had a very minute difference 
that might be due to smaller sample size. But, in 
another study by Brendan Doyle et al, the cumulative 
incidence rate of stent thrombosis at the first 30 days 
after the surgery was 5% which was in accordance 
with the present study.12 However, in another study it 
was concluded that doubling the Clopidogrel dose 
could reduce mortality, infarction and stent 
thrombosis at the first 15 days after the PCI.8 
The study of Julie et al showed that increased 
maintenance dose of Clopidogrel for one month had 
not any additional effect on platelet activity among 
the patients which was in accordance with the present 
study.13 But, in the study of Dominick et al they have 
came to realize that in high-risk groups, the patients 
with diabetes mellitus who had simultaneous coronary 
artery involvement, increased dose of this drug caused 
exacerbation of anti-platelet activity in the patients.14 
Moreover, the study of Gladding et al, showed that by 
giving 1200 mg initial dose and then repeating a 600 
mg dose after two hours and continuing the treatment 
with maintenance dose of 150 mg daily could have a 
better effect on inhibiting the platelets activity in 
comparison with conventional dose (initial dose of 
600 mg)15 which indicated the necessity of more 
studies for administration of higher dosage for 
preventing stent thrombosis considering its potential 
complications. 
In the study of Aleil et al, double initial and 
maintenance dose showed better effects in the 
laboratory tests in comparison with its conventional 
dose; however, it should be emphasized that clinical 
studies should confirm it.16 
In the study of Tavassoli et al, it was indicated that 
double maintenance dosage of Clopidogrel caused 
lower rates of stent thrombosis and cardiovascular 
incidents compared to conventional dose (P = 0.002); 
however, the complications were similar for both 
groups.17 
In the study of Palmerini et al, it was indicated that 
in patients with acute MI double dose could reduce 
stent thrombosis. But these patients, who were 
associated with high-risk of stent thrombosis, 
excluded from the present study.18 
In the study of Gilles et al, the effect of high 
maintenance dose of Clopidogrel after 15 days in 
2954 patients showed very little reduction in the stent 
thrombosis which was statistically significant.19 
Nevertheless, as indicated, there were different 
results in various studies, but as it was mentioned in 
several recent studies, increased dosage could have 
beneficial effects which were not in accordance with 
the present study. However, the initial dose in the 
present study was 600 mg while it was 300 mg in 
other mentioned studies which might justify lack of 
difference between the two groups of the present 
study. Thereto, considering the very low incidence of 
stent thrombosis, further studies should be done with 
larger sample size. Certainly, it should not be ignored 
that genetic differences, as indicated in the mentioned 
studies, in European and American races could cause 
similarity of the results because pharmacokinetic and 
pharmacodynamics of the drugs are varied in 
different races. Besides, the above mentioned studies 
emphasized that the effect of increased dose might 
have different responses in low risk and high risk 
groups which may not specify this in general 
researches and requires to be conducted in the high 
risk groups separately.  
At the end, it is recommended that future studies 
be done with larger sample size and higher dose and 
over a multi-level medical center particularly in Asian 
and Persian race and in a longer follow up time to 
review late stent thrombosis.  
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